Hims Hers Health Inc is trading at $27.51 (up 5.2%) as the stock continues its strong multi-week rally supported by positive analyst coverage and long-term growth prospects.
- JPMorgan recently initiated coverage with an Overweight rating and a $35 price target, highlighting the platform's significant long-term revenue potential.
- The move appears to be largely stock-specific and driven by sustained positive sentiment, as major market indices remain relatively flat.